STOCK TITAN

Cognetivity Neur - CGNSF STOCK NEWS

Welcome to our dedicated page for Cognetivity Neur news (Ticker: CGNSF), a resource for investors and traders seeking the latest updates and insights on Cognetivity Neur stock.

Cognetivity Neurosciences (CGNSF) delivers AI-powered solutions for cognitive health assessment through its award-winning CognICA platform. This centralized news hub provides investors and healthcare professionals with critical updates on the company's advancements in early dementia detection technology and strategic partnerships.

Discover official announcements regarding clinical collaborations, regulatory progress, and platform enhancements. Our curated feed includes updates on deployments with leading healthcare providers like Mediclinic Group and UC Health, plus insights into cognitive testing innovations shaping modern neurology practices.

Bookmark this page to stay informed about CGNSF's developments in AI-driven brain health solutions. Check regularly for verified updates on product milestones, research findings, and healthcare system integrations that demonstrate the company's leadership in cognitive assessment technology.

Rhea-AI Summary
Cognetivity's CognICA technology shows cost-efficiency and improved clinical outcomes compared to traditional cognitive assessment tools, potentially saving over £40 million per year in healthcare costs. The tool's cost-effectiveness is demonstrated in both primary care and specialized memory clinic settings, with quality-of-life improvements for patients. The broader financial benefits of incorporating CognICA into clinical practice could be substantial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
none
-
Rhea-AI Summary
Cognetivity announces collaboration with UC Health to improve early detection of cognitive impairment in the USA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary
Cognetivity Neurosciences announces collaboration with Mediclinic Group to revolutionize brain health diagnosis and care in the UAE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Cognetivity partners with No Fear Counselling to provide advanced mental health tools
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership AI
-
Rhea-AI Summary
Cognetivity Neurosciences wins Best AI Product in Healthcare award at CogX Festival
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.1%
Tags
AI
-
Rhea-AI Summary
Cognetivity Neurosciences shortlisted for Most Innovative AI Product in Healthcare award at CogX Festival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
AI
Rhea-AI Summary
Cognetivity's ADePT Study demonstrates 93% sensitivity in detecting cognitive impairment in early-stage Alzheimer's disease, outperforming current tests. CognICA's ease of use and speed enable wide-scale deployment. Urgent need for CognICA to be used in primary care for effective treatment with new drugs. Positive outlook for Cognetivity's unique ability to solve the issue of reliable early detection and monitoring in the global battle against Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
-
Rhea-AI Summary
Cognetivity Neurosciences' AI technology, CognICA, is set to play a pivotal role in the early detection and monitoring of Alzheimer's disease following FDA approval of Eisai's Leqembi. The approval means that Leqembi will now be covered for all patients, potentially benefiting millions of sufferers worldwide. CognICA has already demonstrated its effectiveness in detecting early-stage cognitive impairment and monitoring cognitive function in Alzheimer's patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
partnership AI
Cognetivity Neur

OTC:CGNSF

CGNSF Rankings

CGNSF Stock Data

699.04k
76.63M
13.5%
Health Information Services
Healthcare
Link
Canada
Vancouver